Goldman Sachs Maintains Buy on Sagimet Biosciences, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan maintains a Buy rating on Sagimet Biosciences (NASDAQ:SGMT) but lowers the price target from $27 to $23.
May 16, 2024 | 11:47 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs analyst Andrea Tan maintains a Buy rating on Sagimet Biosciences but lowers the price target from $27 to $23.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a more cautious outlook on its short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100